Skip to main content
Premium Trial:

Request an Annual Quote

Geospiza, OpGen Win $100K SBIR for Optical Mapping Sequence Assembly

NEW YORK, July 27 (GenomeWeb News) - Geospiza and OpGen have secured a six-month, $100,000 Phase I Small Business Innovative Research grant from the National Institutes of Health to co-develop genomic sequencing tools based on optical mapping technology, the companies said today.


OpGen and Geospiza said they will use the funding to incorporate the output of optical mapping-based sequencing as input to the Phrap sequence assembly program.


OpGen is developing a sequencing method based on optical mapping, a single-molecule DNA analysis technology that the company claims can eventually be used to sequence whole genomes in minutes.


Geospiza said that the collaboration is in line with its ongoing effort to bring Phrap "up to date for modern assembly needs." In 2002, the company was awarded a $1.1 million SBIR to re-engineer Phrap for this purpose, which the company said will provide "a solid foundation" for the so-called "Optical-Map Phrap" application.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.